| human | Q5 |
| P6178 | Dimensions author ID | 01344760626.72 |
| P496 | ORCID iD | 0000-0002-3792-7120 |
| P108 | employer | Fred Hutchinson Cancer Research Center | Q1452369 |
| P734 | family name | Holland | Q1624734 |
| Holland | Q1624734 | ||
| Holland | Q1624734 | ||
| P735 | given name | Eric | Q12788459 |
| Eric | Q12788459 | ||
| P106 | occupation | researcher | Q1650915 |
| Q42052679 | 53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma |
| Q89291590 | A De Novo Mouse Model of C11orf95-RELA Fusion-Driven Ependymoma Identifies Driver Functions in Addition to NF-κB |
| Q24615790 | A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle |
| Q57274885 | A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle |
| Q34977187 | A high-content assay strategy for the identification and profiling of ABCG2 modulators in live cells |
| Q96348394 | A kinase-deficient NTRK2 splice variant predominates in glioma and amplifies several oncogenic signaling pathways |
| Q34126248 | A mathematical methodology for determining the temporal order of pathway alterations arising during gliomagenesis |
| Q36795613 | A physical sciences network characterization of non-tumorigenic and metastatic cells |
| Q39561683 | ABCG2 regulates self-renewal and stem cell marker expression but not tumorigenicity or radiation resistance of glioma cells |
| Q39783570 | Activated EGFR signaling increases proliferation, survival, and migration and blocks neuronal differentiation in post-natal neural stem cells |
| Q28307186 | Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene |
| Q34755317 | An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice |
| Q55467648 | An update on mouse brain tumor models in cancer drug discovery. |
| Q91211240 | Analysis and visualization of linked molecular and clinical cancer data by using Oncoscape |
| Q37881599 | Animal models to study cancer-initiating cells from glioblastoma |
| Q91630838 | Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma |
| Q66679168 | Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma |
| Q35144458 | Astrocyte differentiation states and glioma formation |
| Q34185886 | Astrocyte-specific expression patterns associated with the PDGF-induced glioma microenvironment. |
| Q31085801 | Big data visualization identifies the multidimensional molecular landscape of human gliomas |
| Q81428472 | Bioluminescence technology for imaging cell proliferation |
| Q48433537 | Brain tumor treatment increases the number of cancer stem-like cells |
| Q112297125 | C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation |
| Q94404617 | CBIO-12. GTP METABOLIC SWITCH LEADS TO NUCLEOLAR TRANSFORMATION AND MALIGNANT GROWTH OF GLIOBLASTOMA |
| Q46719721 | CS-19PDGF SIGNALING DEPENDENCE IN PRONEURAL GLIOBLASTOMA, THE BEGINNING BUT NOT THE END. |
| Q34993852 | CSF-1R inhibition alters macrophage polarization and blocks glioma progression |
| Q94149314 | CSIG-17. CHARACTERIZATION OF AN ALTERNATIVELY SPLICED NTRK2 VARIANT IN GLIOMA: EMPLOYING NOVEL REAGENTS TO UNCOVER NOVEL FUNCTIONS |
| Q37141755 | Cancer stem cells and survival pathways |
| Q36528386 | Candidate pathways for promoting differentiation or quiescence of oligodendrocyte progenitor-like cells in glioma |
| Q48959027 | Cell type-specific tumor suppression by Ink4a and Arf in Kras-induced mouse gliomagenesis |
| Q91410839 | Challenges to curing primary brain tumours |
| Q97519905 | Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis |
| Q36640215 | Constitutive activation of Raf-1 induces glioma formation in mice |
| Q92616979 | Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9 |
| Q55456670 | Copy number profiling across glioblastoma populations has implications for clinical trial design. |
| Q93521693 | Correction: Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma |
| Q39884714 | Corticosteroids compromise survival in glioblastoma |
| Q38609989 | Cyclin D1 and cdk4 mediate development of neurologically destructive oligodendroglioma |
| Q26825975 | DNA damage response and growth factor signaling pathways in gliomagenesis and therapeutic resistance |
| Q36723763 | DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases |
| Q28730443 | DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma |
| Q63213728 | Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations |
| Q36021554 | Developmental neurobiology and the origin of brain tumors |
| Q38335045 | Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model |
| Q42827324 | Dose-dependent effects of platelet-derived growth factor-B on glial tumorigenesis |
| Q33924541 | Dynamic small-animal PET imaging of tumor proliferation with 3'-deoxy-3'-18F-fluorothymidine in a genetically engineered mouse model of high-grade gliomas |
| Q39664017 | EGFR signaling is differentially activated in patient-derived glioblastoma stem cells |
| Q55055867 | EPND-09. THE ONCOGENIC EFFECT OF C11ORF95-RELA FUSION MOSTLY DERIVES FROM FACTOR OTHER THAN NF-ΚB ACTIVATION IN SUPRATENTORIAL EPENDYMOMA. |
| Q52088111 | Early detection and prognosis of ovarian cancer using serum YKL-40. |
| Q37217995 | Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model |
| Q42409068 | Evidence for and against regional differences in neural stem and progenitor cells of the CNS. |
| Q36520705 | Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model. |
| Q48523844 | Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma |
| Q37838362 | Genetic modeling of gliomas in mice: new tools to tackle old problems |
| Q101050565 | Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses |
| Q34508688 | Genetically engineered models have advantages over xenografts for preclinical studies |
| Q37348716 | Genetically engineered mouse models of brain cancer and the promise of preclinical testing |
| Q34324259 | Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO |
| Q39996274 | Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas |
| Q30885944 | Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations |
| Q38050180 | Glioblastoma: molecular analysis and clinical implications. |
| Q49136120 | Glioma Stem-like Cells Keep Their H3.3 Variant Levels at Bay. |
| Q37205122 | Glioma formation, cancer stem cells, and akt signaling |
| Q100454881 | Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression |
| Q35606075 | Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo |
| Q34419969 | Guiding brain tumor resection using surface-enhanced Raman scattering nanoparticles and a hand-held Raman scanner. |
| Q36970342 | High Precision Imaging of Microscopic Spread of Glioblastoma with a Targeted Ultrasensitive SERRS Molecular Imaging Probe |
| Q90913547 | Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors |
| Q39677282 | Human glioblastoma-associated microglia/monocytes express a distinct RNA profile compared to human control and murine samples. |
| Q92353570 | IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma |
| Q36295318 | Identification of global alteration of translational regulation in glioma in vivo |
| Q37702083 | In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. |
| Q100408679 | Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients |
| Q52597914 | Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. |
| Q36213745 | Inferring transcriptional and microRNA-mediated regulatory programs in glioblastoma |
| Q48476506 | Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. |
| Q35880328 | Insulin-like growth factor binding protein 2 promotes glioma development and progression |
| Q35779256 | Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response |
| Q49118867 | Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas. |
| Q37281335 | Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas |
| Q47827323 | Loss of host-derived osteopontin creates a glioblastoma-promoting microenvironment. |
| Q28584911 | Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis |
| Q37267797 | MEF promotes stemness in the pathogenesis of gliomas |
| Q41687215 | MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials |
| Q41661510 | MYC expression promotes the proliferation of neural progenitor cells in culture and in vivo |
| Q35609613 | MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas |
| Q48166724 | Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma |
| Q37581947 | Mathematical modeling of PDGF-driven glioblastoma reveals optimized radiation dosing schedules |
| Q96680920 | Mathematical modeling of PDGF-driven glioma reveals the dynamics of immune cells infiltrating into tumors |
| Q58121730 | Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity |
| Q90139904 | Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma |
| Q41843698 | Modeling Adult Gliomas Using RCAS/t-va Technology |
| Q40095085 | Molecular imaging of Akt kinase activity |
| Q46797237 | Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. |
| Q34083282 | Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma |
| Q31062292 | Mouse models of brain tumors and their applications in preclinical trials |
| Q33711322 | Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery |
| Q97072841 | Multimodal single-cell analysis reveals distinct radioresistant stem-like and progenitor cell populations in murine glioma |
| Q42259199 | Mutant IDH1 regulates the tumor-associated immune system in gliomas |
| Q48018806 | Nanoparticle-mediated knockdown of DNA repair sensitizes cells to radiotherapy and extends survival in a genetic mouse model of glioblastoma. |
| Q88669747 | Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies |
| Q34974379 | Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum |
| Q35622926 | Notch signaling enhances nestin expression in gliomas |
| Q47421825 | Oncogenic Ras and Akt Signaling Contribute to Glioblastoma Formation by Differential Recruitment of Existing mRNAs to Polysomes |
| Q45916518 | Oncogenic signaling is dominant to cell of origin and dictates astrocytic or oligodendroglial tumor development from oligodendrocyte precursor cells. |
| Q38955683 | Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. |
| Q35098731 | Overexpression of c-MYC promotes an undifferentiated phenotype in cultured astrocytes and allows elevated Ras and Akt signaling to induce gliomas from GFAP-expressing cells in mice |
| Q94150979 | PATH-51. DNA COPY NUMBER PROFILING ACROSS GLIOBLASTOMA POPULATIONS HAS IMPLICATIONS FOR CLINICAL TRIAL DESIGN |
| Q34164924 | PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas |
| Q94353997 | PM-15C11orf95-RELA FUSION ALONE IS SUFFICIENT TO FORM HUMAN SUPRATENTORIAL EPENDYMOMA-LIKE TUMOR IN MICE |
| Q42148487 | PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells |
| Q45835036 | PTPS-23A NOVEL ROLE FOR NEUROTROPHIN SIGNALING IN PEDIATRIC ATYPICAL TERATOID RHABDOID TUMORS. |
| Q90700444 | Patterns of Failure After Stereotactic Radiosurgery for Recurrent High-Grade Glioma: A Single Institution Experience of 10 Years |
| Q28743461 | Perifosine and CCI 779 co-operate to induce cell death and decrease proliferation in PTEN-intact and PTEN-deficient PDGF-driven murine glioblastoma |
| Q40384702 | Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo |
| Q39741684 | Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells |
| Q35114080 | Personalized medicine for gliomas |
| Q91953583 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma |
| Q92037935 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma |
| Q102334303 | Phenotypic characterization with somatic genome editing and gene transfer reveals the diverse oncogenicity of ependymoma fusion genes |
| Q36716050 | Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment |
| Q37318631 | Preclinical evaluation of radiation and perifosine in a genetically and histologically accurate model of brainstem glioma |
| Q34130984 | Protein phosphatase 2A mediates dormancy of glioblastoma multiforme-derived tumor stem-like cells during hypoxia |
| Q48167510 | Putting Glioblastoma in Its Place: IRF3 Inhibits Invasion |
| Q94153744 | RTHP-27. PATTERNS OF FAILURE AFTER STEREOTACTIC RADIOSURGERY FOR RECURRENT HIGH-GRADE GLIOMA: A SINGLE INSTITUTION EXPERIENCE OF 10 YEARS |
| Q48342646 | Radiation resistance and stem-like cells in brain tumors. |
| Q33960280 | Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression |
| Q92437813 | Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology' |
| Q48385504 | Reply: Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels |
| Q43058662 | Rethinking glioma treatment strategy |
| Q94354229 | SM-06DEXAMETHASONE USE DURING RADIOTHERAPY IN HIGH-GRADE GLIOMA: AN INSTITUTIONAL REVIEW |
| Q55462328 | Self-renewal does not predict tumor growth potential in mouse models of high-grade glioma. |
| Q35419401 | Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas |
| Q28513336 | Somatic cell type specific gene transfer reveals a tumor-promoting function for p21(Waf1/Cip1) |
| Q39009613 | Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies |
| Q37362145 | Sonic hedgehog pathway activation is induced by acute brain injury and regulated by injury-related inflammation |
| Q34332418 | Sox2, a marker for stem-like tumor cells in skin squamous cell carcinoma and hedgehog subgroup medulloblastoma |
| Q38967517 | Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas |
| Q92094518 | Stochastic growth pattern of untreated human glioblastomas predicts the survival time for patients |
| Q41595099 | Suppression of autophagy impedes glioblastoma development and induces senescence |
| Q35552182 | Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging. |
| Q55007590 | TM-15GLUTAMINE BASED PET IMAGING FACILITATES ENHANCED METABOLIC DETECTION OF GLIOMAS IN VIVO. |
| Q94147157 | TMIC-05. ABSCOPAL IMMUNE RESPONSE IN GLIOBLASTOMA ELICITED BY MIR124-ATTENUATED ONCOLYTIC HERPES SIMPLEX VIRUS 1 ARMED WITH UL16 BINDING PROTEIN 3 |
| Q94147276 | TMIC-13. EFFICACY OF RETINOIC ACID IN REVERSING IMMUNE EVASION IN IDH MUTANT GLIOMAS |
| Q94407505 | TMIC-41. LOSS OF HOST-DERIVED OSTEOPONTIN CREATES A GLIOBLASTOMA-PROMOTING MICROENVIRONMENT |
| Q94151990 | TMIC-53. IDENTIFICATION OF MYELOID CELL-DERIVED TRANSCRIPTS IN GLIOBLASTOMA |
| Q94149467 | TMOD-30. ANTI-PD-L1 ANTIBODY ENHANCES RADIATION INDUCED ABSCOPAL RESPONSE IN MURINE BRAIN TUMORS |
| Q48340415 | TRRAP and the maintenance of stemness in gliomas |
| Q92662664 | Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas |
| Q37736255 | Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma |
| Q96136088 | Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas |
| Q37588400 | The ABCG2 resistance network of glioblastoma |
| Q24657924 | The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo |
| Q41491918 | The SHH/Gli pathway is reactivated in reactive glia and drives proliferation in response to neurodegeneration-induced lesions |
| Q37858940 | The brain tumor microenvironment. |
| Q37989468 | The brain tumor microenvironment. |
| Q34768422 | The characteristics of astrocytomas and oligodendrogliomas are caused by two distinct and interchangeable signaling formats. |
| Q37553466 | The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants |
| Q64064514 | The molecular landscape of adult diffuse gliomas and relevance to clinical trials |
| Q37780433 | The perivascular niche microenvironment in brain tumor progression |
| Q34023540 | The probable cell of origin of NF1- and PDGF-driven glioblastomas |
| Q57274886 | The role of radiotherapy following gross-total resection of atypical meningiomas |
| Q33778409 | The therapeutic implications of plasticity of the cancer stem cell phenotype |
| Q33744491 | The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas |
| Q38732546 | Tissue mechanics promote IDH1-dependent HIF1α-tenascin C feedback to regulate glioblastoma aggression |
| Q89721953 | Translating Basic Science Discoveries into Improved Outcomes for Glioblastoma |
| Q35808646 | Trapping the mouse genome to hunt human alterations |
| Q42558518 | Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization |
| Q90781005 | Tumor endothelial cell up-regulation of IDO1 is an immunosuppressive feed-back mechanism that reduces the response to CD40-stimulating immunotherapy |
| Q33779433 | Validation of a high-content screening assay using whole-well imaging of transformed phenotypes |
| Q89747808 | Variability in estimated gene expression among commonly used RNA-seq pipelines |
| Q89899719 | Wnt-mediated endothelial transformation into mesenchymal stem cell-like cells induces chemoresistance in glioblastoma |
| Q93063888 | YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis |
| Q83578684 | YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma |
| Q55469339 | YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. |
| Q53363779 | Yin and yang: cancer-implicated miRNAs that have it both ways. |
| Q91793916 | cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV" |
| Q93041575 | cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas |
| Q40407116 | mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma |
| Q34221665 | miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis |
| Q30450445 | p190RhoGAP can act to inhibit PDGF-induced gliomas in mice: a putative tumor suppressor encoded on human chromosome 19q13.3. |
| Q39713008 | p27 deficiency is associated with migration defects in PDGF-expressing gliomas in vivo |
Search more.